Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field

Sasha Abdallah Fahme, Kathleen F Walsh, Vanessa Rouzier, Puja Chebrolu, Hyasinta Jaka, Justin Roy Kingery, Fouad M Fouad, Jyoti S Mathad, Jennifer A Downs, Margaret McNairy

INTRODUCTION
Efforts to contain and respond to the novel COVID-19 in both high-income and low-income countries remain extremely challenging. Resource-constrained countries face the additional obstacles of limited health infrastructure and inability to socially distance due to crowded and often multigenerational living conditions. As Western nations begin mass vaccination campaigns, many countries in the Global South may not receive the vaccine for months or years. Until this ‘vaccination gap’ is filled, we must prioritise community-based prevention measures, while continuing to share and learn from each other’s clinical experiences, adapting management approaches to severely resource-limited settings in which vaccination may be delayed.

We are global health physicians who have been COVID-19 first responders in hospitals and clinics in both New York City and diverse low-income and middle-income countries (LMICs) across Africa, the Middle East and the Caribbean. We report our experiences in the field across these various settings with the goal to summarise our practices in the prevention and management of this disease, emphasising evidence-based interventions that can be realistically implemented in LMICs. All efforts should be contextualised to the individual setting, which is partially dependent on the capacity of each country’s health systems.

COVID-19 PREVENTION RECOMMENDATIONS
Community-based prevention interventions are paramount to ensure a successful public health response. In New York City, government-mandated social distancing measures were delayed by nearly 2 weeks following the first confirmed case of COVID-19 on 3 March 2020, after which 5072 more were diagnosed. Emphasis on prevention should be placed with all the more urgency in resource-limited countries. LMICs have a rich history of robust prevention interventions, community partnerships and education to confront prior epidemics.

Community-based interventions
The SARS-CoV-2 is spread primarily via respiratory droplets and through contact with contaminated surfaces. Preventative methods such as social distancing are impractical in densely populated areas in LMICs, particularly as strict lockdown measures depress fragile economies. However, some African governments have taken steps to reinforce social distancing by administering household surveys assessing the feasibility of safe and responsible self-isolation.

Increased handwashing is an effective behavioural change that can be promoted by public health organisations and healthcare workers (HCWs). To facilitate hand hygiene, our colleagues in Haiti erected 100-gallon water barrels with soap for handwashing at street corners in Port-au-Prince. Similar measures have been implemented across Tanzania, as depicted in figure 1. In Lebanon, where over 30% of the world’s highest per capita refugee population reside in overcrowded slums, the United Nations High Commission for Refugees provided infection prevention training and distributed soap and hygienic kits to refugees.
Healthcare-based interventions

Personal protective equipment (PPE) for HCWs is essential. There is general consensus that HCWs should cover all skin and mucus membranes that may be exposed to the virus, typically by using some form of gown, gloves, mask and protective eye wear. PPE should be composed of reusable items that can be easily decontaminated to maximise safe reuse among multiple patients.

New York City hospitals, including our own, experienced PPE shortages that required repurposing of non-traditional materials. Eye protection ranged from industrial lab goggles to three-dimensional printed face shields. Some hospitals used garbage bags as gowns. In March–April 2020, we reused the same N95 mask under a disposable surgical mask over several shifts, until it became visibly soiled or imperfectly sealed. Evidence since that time has shown that N95 mask reuse for greater than 2 days is associated with a 41% chance of failure compared with 9% risk when used for 2 days or less (OR 7.1; 95% CI 2.5 to 20; p<0.0001). 

Additionally, newer studies have identified multiple effective methods of heat-based and chemical-based N95 mask decontamination and preservation. In particular, moist heat treatment emerged as among the most effective approaches to inactivating SARS-CoV-2 while maintaining the structural integrity of the mask. While some of these treatments may be impractical for wide application in LMICs, one study found that a similar, low-cost, moist heat-based decontamination method using widely available utensils could be both feasible and effective in resource-limited settings.

LMIC governments should prepare for shortages by increasing local production of masks. For instance, the Tanzanian Ministry of Health commissioned local industries to produce masks and gowns for distribution in their health systems. PPE can also be conserved by the physical separation of confirmed SARS-CoV-2 cases, thus enabling HCWs to reuse PPE when consecutively examining patients. In our institution, plastic tarps were erected to separate patient areas when developing makeshift clinical spaces. Using extended tubing, we kept intravenous medication pumps outside of patient rooms, such that medications could be titrated without using PPE. In some settings, HCWs may conserve PPE by using free smartphone applications such as WhatsApp to remotely interview and triage patients.

Rigorous hand hygiene has also been suggested to limit nosocomial transmission among HCWs. In centres with limited or no running water, the WHO-recommended hand rub solutions which contain at least 30% alcohol have been shown to inactivate SARS-CoV-2 and may be an effective alternative.

COVID-19 TREATMENT RECOMMENDATIONS

We describe management approaches to COVID-19 in resource-constrained settings. These suggestions are informed by our clinical experiences with COVID-19.
patients in New York City and LMICs, consultation of Society guidelines, and a rapid review of the available evidence, much of which is based on observational data. Apart from dexamethasone, which to date is the only therapeutic demonstrating a mortality benefit, the interventions discussed are primarily supportive. Table 1 summarises the suggested low-cost supportive interventions that may be realistically implemented in resource-constrained settings.

Non-pharmacological therapies

Oxygen

Hypoxaemic respiratory failure is likely the most common cause of death in patients with COVID-19. Oxygen remains the mainstay of therapy, and in some settings may be the only available intervention. We and others anecdotal observed that many patients with COVID-19 may uniquely present with severe though asymptomatic hypoxia (oxygen saturation, SpO₂ < 85%). While initially adopting an early intubation strategy for these patients, we soon realised that this approach was both unsustainable due to limited ventilator supplies, and potentially ineffective, as preserved lung compliance among some patients suggested an underlying mechanism of respiratory failure other than acute respiratory distress syndrome (ARDS). We adjusted our clinical practice to include the presence of respiratory distress when considering ICU admission for severely hypoxic patients.

In this paper, we focus on non-invasive oxygen therapy, as the majority of resource-poor countries will be without mechanical ventilation. For an excellent analysis of mechanical ventilation in COVID-19, we suggest Tobin. We similarly do not comment on non-invasive positive pressure ventilation, as this was rarely used in our setting, and may not provide additional benefits over supplemental oxygen in the treatment of COVID-19.

Early initiation of oxygen supplementation anecdotal helped delay or prevent mechanical ventilation among patients with resting hypoxia (SpO₂ < 92%) hospitalised with COVID-19 at our institution. Using non-invasive methods, the fraction of inspired oxygen (FiO₂) can only be estimated and depends on the mode of delivery, with additional variability based on the quality of the device. For instance, a maximal rate of 6 L of oxygen per minute delivered by nasal cannula provides roughly 45% FiO₂. The same amount of oxygen delivered through a ‘partial rebreather’ face mask may provide closer to 60% FiO₂. A ‘non-rebreather’ mask may provide up to 95% FiO₂ while consuming up to 15 L of oxygen per minute. Oxygen monitoring in low-resource settings may be facilitated by portable pulse oximetry, a fairly inexpensive and reusable tool that may accurately identify patients at highest risk of decompensation. However, clinicians should bear in mind recent findings that occult hypoxaemia is less frequently detected by pulse oximetry in black than white patients.

Piped oxygen availability may be limited in severely resource-constrained settings. In such settings, we recommend the decontamination and reuse of partial rebreather masks, which each cost approximately US$2–US$4, as the more efficient utilisation of oxygen represents an outstanding return on investments. We recommend adjusting supplemental oxygen to achieve a peripheral saturation of 92%–96% or respiratory rate < 25 in all hypoxic patients with COVID-19.

Awake prone positioning

Early prone positioning of awake, non-mechanically ventilated COVID-19 patients is a simple, no-cost intervention found in our practice to be highly effective at improving hypoxia. Observational data are inconsistent, with some studies demonstrating that awake proning may improve hypoxia and delay or prevent intubation, and others finding no clinical benefit. Several clinical trials examining the role of awake prone positioning in this context are underway.

Prone positioning homogenises aeration by decreasing intrapulmonary shunting and promoting recruitment of the dorsal lung segments. On this basis, we extended this practice to all awake, non-mechanically ventilated COVID-19 patients with moderate-to-severe hypoxia, with anecdotal improvement in oxygenation.

We recommend the early use of interval prone positioning on all hemodynamically stable, neurologically oriented COVID-19 patients with peripheral SpO₂ below 92%. Suggested contraindications to this practice include an inability to call for help, unstable fractures, pregnancy or presence of a chest tube.

Pharmacological therapies

Glucocorticoids

There is high-quality evidence to support the use of glucocorticoids in the management of COVID-19. Corticosteroids may be valuable in the setting of hyperinflammation, though initially we were reluctant to use them to treat COVID-19 based on data from prior novel coronavirus outbreaks, which showed no benefit, and possible complications, with their use. We began to adapt our practices, however, first after a retrospective cohort study of 84 patients with COVID-19 and ARDS demonstrated a lower mortality risk among those who received methylprednisolone (HR 0.38; 95% CI 0.20 to 0.72; p = 0.003). Soon thereafter, an open-label randomised clinical trial of 2104 patients hospitalised with COVID-19 in the USA found a mortality benefit with dexamethasone use among those receiving non-invasive oxygenation (rate ratio 0.82; 95% CI 0.72 to 0.94; p<0.001) and mechanical ventilation (rate ratio 0.64; 95% CI 0.51 to 0.81; p<0.001). Glucocorticoids are inexpensive and frequently available in LMICs. We recommend their initiation in any patient with COVID-19 and hypoxia, defined as SpO₂ < 92%, who does not otherwise have a contraindication to their use.

Acetaminophen/paracetamol

A total of 24%–94% of patients hospitalised with COVID-19 will experience a fever during their disease course. Fevers increase metabolic oxygen consumption and thus worsen dyspnoea and hypoxia. Though
### Table 1  Suggested low-cost interventions with supporting evidence for the clinical management of COVID-19 pneumonia in resource-constrained settings

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Evidence</th>
<th>Clinical use</th>
<th>Clinical settings</th>
<th>LMIC availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-invasive supplemental oxygen (via NC or NRB mask) guided by pulse-oximetry</td>
<td>Mainstay of therapy and recommended for use in COVID-19 based on expert consensus. Anecdotally beneficial in COVID-19 with improvement in hypoxia and work of breathing.</td>
<td>All patients with suspected or confirmed COVID-19 with respiratory distress, RR &gt;20, or resting SpO₂ &lt;92%.</td>
<td>Hospital</td>
<td>Variable; pulse oximeter frequently available; piped oxygen may be limited in severely resource-constrained settings.</td>
</tr>
<tr>
<td>Awake prone positioning</td>
<td>Inconsistent observational data; Some studies suggest improvement in hypoxia among patients with severe respiratory failure and COVID-19 while others found no benefit. Anecdotally shown to be effective in improving hypoxia in COVID-19 patients who are oriented.</td>
<td>All patients with suspected or confirmed COVID-19 with RR &gt;20 or resting SpO₂ &lt;92%</td>
<td>Hospital; Clinic; Home.</td>
<td>Unlimited.</td>
</tr>
<tr>
<td>Standing acetaminophen or paracetamol</td>
<td>Improves fevers and respiratory distress by reducing oxygen consumption and recommended for use in COVID-19. Anecdotally effective in treating myalgias and improving work of breathing in COVID-19 patients.</td>
<td>All patients with suspected or confirmed COVID-19 with respiratory distress, RR &gt;20, or resting SpO₂ &lt;92% irrespective of fever curve.</td>
<td>Hospital; Clinic; Home.</td>
<td>Widely available.</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Mortality benefit in hypoxic patients hospitalised with COVID-19.</td>
<td>All patients with suspected or confirmed COVID-19 pneumonia and resting SpO₂ &lt;92%</td>
<td>Hospital/ICU; Clinic; Home.</td>
<td>Frequently available.</td>
</tr>
<tr>
<td>Heparin or LMWH</td>
<td>Improvement in 28-day mortality among select patients with COVID-19. Anecdotal observations of high rates of hemodynamically significant thromboembolic disease in COVID-19 requiring LMWH use.</td>
<td>Patients with suspected or confirmed COVID-19 with symptom duration &gt;7 days, minimal bleeding risk, and one of the following: persistent temperature &gt;39.4°C, respiratory failure, shock, kidney failure or clinically evident thromboembolic disease.</td>
<td>Hospital/ICU.</td>
<td>Variable drug availability; may be limited in more resource-constrained areas. Further limitations in laboratory testing limit safe administration in many LMICs.</td>
</tr>
<tr>
<td>Low-dose aspirin</td>
<td>Observational data demonstrated aspirin independently associated with lower risk of mechanical ventilation, ICU admission, and inhospital mortality among hospitalised patients with COVID-19.</td>
<td>Patients with suspected or confirmed COVID-19 with symptom duration &gt;7 days, minimal bleeding risk, and one of the following: persistent temperature &gt;39.4°C, respiratory failure, shock, kidney failure or clinically evident thromboembolic disease.</td>
<td>Hospital/ICU in which anticoagulation is not available.</td>
<td>Widely available.</td>
</tr>
</tbody>
</table>

ICU, intensive care unit; LMICs, low-income and middle-income countries; LMWH, low-molecular-weight heparin; NC, nasal cannula; NRB, non-rebreather; RR, respiratory rate; SpO₂, oxygen saturation.
Acetaminophen has not been studied in COVID-19, it is nonetheless recommended for use in this context.22 Our experience with scheduled acetaminophen irrespective of fever curve has shown not only a reduction in fever occurrence but also improvement in work of breathing without significant hepatic toxicity. This drug is inexpensive and widely available globally. Notably, while non-steroidal anti-inflammatory drugs (NSAIDs) may be an alternative for patients with contraindications to paracetamol, these drugs have been anecdotaly linked to poor outcomes in this setting.38 We have generally limited NSAID use in our practice, primarily due to a high prevalence of kidney injury.37

**Chloroquine and hydroxychloroquine**

Chloroquine and hydroxychloroquine have shown in vitro activity against SARS-CoV-2, prompting their use in patients early in the COVID-19 pandemic.39 40 However, data on in vivo activity indicated lack of effectiveness.41 42 The initially promising study of hydroxychloroquine in conjunction with azithromycin has since been retracted due to concerns over its methodology.43 A small randomised trial from China showed hydroxychloroquine had no effect on viral clearance compared with standard of care.41 A retrospective study of 368 patients with COVID-19 in the USA found an association of increased overall mortality with hydroxychloroquine use (HR 2.61; 95% CI 1.1 to 6.17; p=0.03).44 Most recently, a multicentre, blinded, placebo-controlled randomised clinical trial of 479 hospitalised adults in the USA with COVID-19 respiratory disease showed no clinical benefit at 14 days to support hydroxychloroquine use.45 Based on the current evidence, we do not recommend the use of these medications.

**Anticoagulation**

Haemostatic derangement appears to be a key component of severe COVID-19 illness. An observational study of 3334 patients hospitalised with COVID-19 across four New York City hospitals found that 16% of all patients and 29% of ICU patients experienced a thrombotic event, which included deep vein thrombosis (3.9%), pulmonary embolism (3.2%), myocardial infarction (8.9%) and ischaemic stroke (1.6%), during their hospitalisation.46 Further, thrombosis was independently associated with critical illness, elevated D-dimer levels (p<0.001), and all-cause mortality (HR 1.82; 95% CI 1.54 to 2.15; p<0.001).46

Empiric anticoagulation may be useful in select patients. A retrospective analysis of 449 patients with COVID-19 showed that, among patients with elevated inflammatory markers, prophylactic heparin use conferred a lower 28-day mortality rate (32.2% vs 52.4%; p=0.017).47 Similarly, our hospital and others in New York City developed their own anticoagulation guidelines.

Prophylactic anticoagulation in this setting is recommended too by Society guidelines, often guided by inflammatory biomarkers, which may be useful for prognostication.46 48 In settings with limited laboratory capacity, however, the decision of whether to initiate anticoagulation may be determined by clinical severity including the presence of severe hypoxia (SpO2 ≤90%), persistent high fever (>39.4°C) despite standing paracetamol use, abdominal organomegaly and/or shock.

**Aspirin**

Unfractionated and low-molecular-weight heparin may not be available in many resource-limited settings. If anticoagulation is not possible, it may be reasonable to trial low dose (81 mg) aspirin. The inexpensive, widely available drug has been shown to inhibit pulmonary neutrophilia in the setting of lipopolysaccharide-induced ARDS,49 and was suggested to be a safe and effective alternative to anticoagulation in preventing postoperative venous thromboembolism in a cohort of postoperative patients.50 More recently, a multicentre retrospective study of 412 adults with COVID-19 hospitalised in the USA found that aspirin use was independently associated with a lower risk of mechanical ventilation (HR 0.56; 95% CI 0.37 to 0.85; p=0.007), ICU admission (HR 0.57; 95% CI 0.38 to 0.85; p=0.005) and in-hospital mortality (HR 0.53; 95% CI 0.31 to 0.90; p=0.02), though no differences were observed in thrombosis.51 Concomitant aspirin and anticoagulation use in patients with venous thromboembolism is associated with an increased risk of clinically significant bleeding (HR 1.70, 95% CI 1.38 to 2.11) and has not been studied in the setting of COVID-19.52 We, therefore, only recommend aspirin use in patients with COVID-19 respiratory illness in whom anticoagulation is not feasible and who do not have any contraindications.

**Antiviral therapies**

Remdesivir was shown in a double-blind, randomised placebo-controlled trial of 1062 adults hospitalised with COVID-19 in the USA to be superior to placebo on the primary outcome of time to recovery (rate ratio 1.29; 95% CI 1.12 to 1.49; p<0.001), but did not confer a statistically significant survival benefit.53 Triple therapy with interferon-beta-1B, lopinavir-ritonavir and ribavirin also showed effectiveness in reducing duration of symptoms and hospitalisation among a randomised phase 2 trial of 144 participants.54 Despite this promising data, these drugs are not universally available, with their use still confined to clinical trials. An increase in production and widespread dissemination of these medications is needed prior to their routine use in both high-resource and low-resource settings.

**Monoclonal antibodies and convalescent plasma**

The US Food and Drug Administration has recently granted emergency use authorisation for monoclonal antibody treatments in high-risk outpatients—but not those hospitalised—with COVID-19 including immunosuppressed persons and those with certain comorbidities, after preliminary data from placebo-controlled trials demonstrated a reduction in viral load and potentially decreased risk of hospitalisation.55 56 In addition to their...
expense, these medications are oftentimes impractical for use given their high-risk side effect profile, which has been cited as a primary factor in their underutilisation in even high-resource settings.\(^5\) Convalescent plasma may be more readily available in LMICs, though a recent multicentre, double-blinded, placebo-controlled randomised trial in Argentina found no mortality benefit from convalescent plasma among patients hospitalised with severe COVID-19 pneumonia.\(^5\) Similarly, a randomised controlled trial conducted across 39 hospitals in India found that convalescent plasma use did not confer a mortality benefit nor reduction in severe disease among patients hospitalised with moderate COVID-19 illness.\(^5\) Additionally, case studies suggest that convalescent plasma use, particularly in immunosuppressed individuals with prolonged viral replication, may be associated with lower susceptibility to neutralising antibodies.\(^6\) At this time, we do not recommend convalescent plasma use in patients with moderate to severe COVID-19 illness, given its unclear benefit and potentially harmful public health implications.

**CONCLUSION**

The COVID-19 pandemic presents unique challenges to healthcare providers worldwide, and particularly those working in resource-limited settings. As harder hit wealthy nations begin vaccination campaigns, severe global inequities in vaccine distribution are feared to worsen the pandemic in low-income countries, where nine out of 10 individuals will not have access to any vaccine in the coming year.\(^5\) Aside from ubiquitous vaccination, there is no solution to overcome this pandemic, as evidenced by the diversity of management approaches adopted by institutions even just in New York City. Until vaccines are universally available, emphasis on prevention with community-based interventions aimed at reducing stigma and increasing awareness to reduce transmission is essential. This pandemic knows no geopolitical national boundaries, and we must learn from each other’s experiences and mistakes to prepare the next epicentre’s response.

**Author affiliations**

1. Center for Global Health Research, Cornell University Joan and Sanford I Weill Medical College, New York, New York, USA
2. Department of Health Promotion and Community Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
3. GHSKIO, Port-au-Prince, Haiti
4. Catholic University of Health and Allied Sciences, Mwanza, Mwanza, Tanzania
5. Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon

**Acknowledgements** We thank Dr. Daniel Fitzgerald, Director of the Weill Cornell Center for Global Health, for his thoughtful review and support of this manuscript. We are grateful to Dr. Arthur Evans, Section Chief of Hospital Medicine, Division of General Internal Medicine, Weill Cornell Medicine, for his visionary leadership during this unprecedented pandemic. We are thankful to all our healthcare colleagues working tirelessly to provide patient care in this pandemic.

**Contributors** SAF conceived of the review, conducted the literature search, and wrote the manuscript. KW contributed to the literature review, writing, reviewing and editing of the manuscript. VR, PC, HJ, JRK, FMF, JSM and JAD were involved in the reviewing, writing and editing of the paper. MM contributed to the writing and supervised the literature search, writing and review of the manuscript. All authors reviewed the final manuscript and approved submission.

**Funding** This work was not supported by any funding sources.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the work is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Sasha Abdallah Fahme http://orcid.org/0000-0003-0265-2582

Kathleen F Walsh http://orcid.org/0000-0002-9001-3918

Puja Chebrolu http://orcid.org/0000-0002-5422-2966

**REFERENCES**


McKinley L. Only one COVID-19 treatment is designed to keep people out of the hospital. Many overburdened hospitals are not offering it. The Washington Post, 2020.


